ESMO25 Breast Cancer Highlights: evERA and SERENA6 | Dana-Farber Cancer Institute

42 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the evERA and SERENA6 trials investigating oral selective estrogen receptor degraders (SERDs), which were presented at ESMO 2025.

For more information about Dana-Farber's Breast Oncology Center, visit https://www.dana-farber.org/cancer-care/treatment/breast-oncology
Categoria
Oncology
Commenta per primo questo video.

Prossimo